Trial Summary
What is the purpose of this trial?This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with lymphoplasmacytic lymphoma. Vaccines made from a person's cancer cells may help the body build an effective immune response to kill cancer cells.
Eligibility Criteria
This trial is for patients with lymphoplasmacytic lymphoma who haven't been treated before. They need a specific type of tumor sample, normal liver function tests, and no severe heart or autoimmune diseases. Participants must be able to consent and follow up, have good physical functioning, and use birth control if necessary.Inclusion Criteria
My lymphoma diagnosis was confirmed with specific tests for IgG, IgA, or IgM.
I can provide a large enough lymph node sample or a bone marrow sample with enough CD20 or CD38+ cells.
I have lymphoplasmacytic lymphoma and haven't been treated yet.
I am fully active or restricted in physically strenuous activity but can do light work.
My kidney function is within the required range.
Exclusion Criteria
I have positive ANA or anti-dsDNA antibodies.
My heart condition severely limits my daily activities.
Treatment Details
The study is testing a vaccine made from the patient's own cancer cells to see if it can trigger the body's immune system to fight the cancer. It also involves checking biomarkers in the lab to understand how well the vaccine works.
1Treatment groups
Experimental Treatment
Group I: Treatment (vaccine therapy)Experimental Treatment2 Interventions
Patients receive autologous lymphoma immunoglobulin-derived scFV-chemokine DNA vaccine ID at 0, 4, and 8 weeks.
Find a clinic near you
Research locations nearbySelect from list below to view details:
M D Anderson Cancer CenterHouston, TX
Loading ...
Who is running the clinical trial?
M.D. Anderson Cancer CenterLead Sponsor
National Cancer Institute (NCI)Collaborator